(MENAFN- GlobeNewsWire - Nasdaq) SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation by its parent company, NKMax Co., Ltd., on preclinical and clinical data from a Phase I/IIa study of SNK01 in combination with cytotoxic chemotherapy in non-small cell lung cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, Illinois from June 2-6, 2023.
Presentation Details:
| Title: | The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study |
| Authors: | Myeong Geun Choi, Gun Woo Son, Dae-Hyun Ko, Wonjun Ji, Jin Kyung Rho, Jae Cheol Lee, Yong Man Kim, Jae Seob Jung, Paul Y. Song, Byeong Gon Yoon, Jong-min Jo, Mi Young Choi, Chang-Min Choi |
| Abstract Number: | 9057 |
| Session Type: | Poster |
| Session Title: | Lung Cancer – Non-Small Cell Metastatic |
| Poster Board Number: | 45 |
| Session Time: | Sunday, June 4, 2023; 8:00 a.m. – 11:00 am CT |
| Location: | Hall A |
Full abstracts will be released at 5:00 pm ET on Thursday, May 25, 2023. Visit the 2023 ASCO Annual Meeting website at for more information.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit .
Internal Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
949-396-6830
External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
MENAFN25052023004107003653ID1106316475
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.